Summary
Cardiac amyloidosis is a rare disease associated with poor prognosis.
Although there is some evidence that cardiac surgery can be offered to
select patients with concomitant valve disease, outcomes following
surgical revascularization are universally poor. Even in highly selected
patients surgical intervention is difficult to justify, and percutaneous
options must be preferred.